ALDH3A1-IN-1

CAS No. 1039855-56-5

ALDH3A1-IN-1( —— )

Catalog No. M35409 CAS No. 1039855-56-5

ALDH3A1-IN-1 (Compound 18) is a potent ALDH3A1 inhibitor with an IC 50 of 1.61 μM. It is more effective than DEAB against patient-derived primary prostate tumor epithelial cells, both as a single agent and in combination with docetaxel .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    ALDH3A1-IN-1
  • Note
    Research use only, not for human use.
  • Brief Description
    ALDH3A1-IN-1 (Compound 18) is a potent ALDH3A1 inhibitor with an IC 50 of 1.61 μM. It is more effective than DEAB against patient-derived primary prostate tumor epithelial cells, both as a single agent and in combination with docetaxel .
  • Description
    ALDH3A1-IN-1 (Compound 18) is a potent inhibitor of ALDH3A1 with an IC50 of 1.61 μM. ALDH3A1-IN-1 is more potent than DEAB against patient-derived primary prostate tumor epithelial cells, as single agents or in combination research with docetaxel.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    NMDAR
  • Recptor
    NMDAR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1039855-56-5
  • Formula Weight
    250.29
  • Molecular Formula
    C13H18N2O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (399.54 mM; Ultrasonic (<60°C)
  • SMILES
    CCCN(CCC)c1ccc(C=O)cc1[N+]([O-])=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Ibrahim AIM, et al. Expansion of the 4-(Diethylamino)benzaldehyde Scaffold to Explore the Impact on Aldehyde Dehydrogenase Activity and Antiproliferative Activity in Prostate Cancer. J Med Chem. 2022 Mar 10;65(5):3833-3848.?
molnova catalog
related products
  • Tiletamine hydrochlo...

    Proposed anesthetic with possible anticonvulsant and sedative properties.

  • Ro 25-6981 Maleate

    Ro 25-6981 Maleate is a potent and selective activity-dependent NMDA receptor blocker, specifically targeting the NR2B subunit (IC50 values are 0.009 μM for NR1C/NR2B and 52 μM for NR1C/NR2A receptor subunit combinations).

  • TCN-201

    TCN-201 is a selective antagonist of NMDA receptors containing the NR2A subunit.